Please login to the form below

Not currently logged in
Email:
Password:

liver cancer

This page shows the latest liver cancer news and features for those working in and with pharma, biotech and healthcare.

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

Although hepatitis C has an effective range of treatments which can effectively cure most patients, hepatitis B remains difficult to treat and can cause cirrhosis, liver failure and liver cancer. ... Chronic hepatitis B affects around 260 million people

Latest news

  • AZ’s Imfinzi plus tremelimumab combo misses again AZ’s Imfinzi plus tremelimumab combo misses again

    AZ notes the CTLA4 inhibitor remains in clinical trials in combination with Imfinzi in NSCLC, SCLC, bladder cancer, head and neck cancer and liver cancer. ... $1.5bn thanks largely to wider use in NSCLC as well as bladder cancer.

  • Lilly posts higher-than-expected profit as new drugs lift outlook Lilly posts higher-than-expected profit as new drugs lift outlook

    Lilly’s dependence on Loxo’s pipeline will grow, given the fact that the company has halted development of three experimental cancer drugs. ... This includes TGF-beta R1 kinase inhibitor galunisertib, which had been in trial in lung and liver cancer.

  • Roche files Tecentriq/Avastin combo in liver cancer Roche files Tecentriq/Avastin combo in liver cancer

    Levi Garraway. “Liver cancer is the most rapidly increasing cause of cancer-related death in the US. ... The filing in liver cancer is an important milestone in Roche’s plans for Tecentriq, which is a latecomer to the checkpoint inhibitor category.

  • AZ’s Imfinzi scores orphan drug status in liver cancer AZ’s Imfinzi scores orphan drug status in liver cancer

    AstraZeneca’s PD-L1 Imfinzi, and anti-CTLA4 antibody tremelimumab, have been granted orphan drug designations (ODD) in the US for liver cancer. ... HCC is the most common form of liver cancer, with more than 750, 000 people worldwide diagnosed with the

  • Roche’s Tecentriq combo scores in first-line melanoma Roche’s Tecentriq combo scores in first-line melanoma

    By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma." said Levi Garraway, chief medical officer ... Roche also has plans to file a

More from news
Approximately 14 fully matching, plus 123 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver). ... of this cancer.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Co-development was another area in which major pharma firms were active, particularly Lilly, which enlarged its work with Boehringer Ingelheim to add in breast cancer programmes and closed a ... NASH and biosimilars. One therapeutic indication that could

  • Pharma deals in April 2015 Pharma deals in April 2015

    The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid. ... Menarini AP will be responsible for the clinical development, regulatory approval and commercialisation of resminostat in all oncological

  • Pharma deals during September 2013 Pharma deals during September 2013

    The lead pipeline candidates are SGI-110, a subcutaneous hypomethylating agent in multiple studies for a variety of haematological and solid tumour oncology indications, including MDS, AML, ovarian cancer and liver ... cancer, and AT13387, a second

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics